Biotech and medtech company SmartCella Holding has successfully raised EUR 50 million (~USD 54 million) in a new share issue. The funding round was backed by investors including Fjärde AP-fonden, AMF Pension, SEB-Stiftelsen, as well as new investors AstraZeneca, Handelsbanken Fonder, and RoosGruppen AB. This round resulted in a pre-money valuation of ~EUR 500 million (~USD 541 million).
The funds procured will be channeled toward the commercialization of SmartCella's Extroducer and the advancement of its cell and mRNA operations. The capital is also planned to expand the company's organizational infrastructure.
Sweden-based SmartCella is a global biotechnology company focused on delivering targeted therapies using its novel delivery platforms. Its portfolio includes the FDA-cleared Extroducer, an endovascular device designed for the precise delivery of therapies to challenging-to-access tumors or organs, as well as cell and mRNA therapies.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.